Table 4.
Patient characteristics by serum ferritin in Japan DOPPS (2009–15)
| Patient characteristic | All | Serum ferritin (ng/mL) |
|||
|---|---|---|---|---|---|
| <50 | 50–99 | 100–199 | ≥200+ | ||
| Patients, n (%) | 2994 | 1012 (34) | 666 (22) | 682 (23) | 634 (21) |
| Demographics | |||||
| Age (years), mean ± SD | 64.9 ± 12.0 | 63.8 ± 11.8 | 64.5 ± 12.5 | 65.6 ± 11.7 | 66.2 ± 12.1 |
| Sex (male), % | 66 | 67 | 65 | 65 | 66 |
| Race (black), % | 0 | 0 | 0 | 0 | 0 |
| Vintage (years), mean ± SD | 7.0 ± 7.4 | 7.6 ± 7.5 | 7.3 ± 7.6 | 6.5 ± 7.6 | 6.0 ± 6.6 |
| HD characteristics | |||||
| Catheter use, % | 1 | 0 | 2 | 1 | 2 |
| Single pool Kt/V, mean ± SD | 1.34 ± 0.30 | 1.36 ± 0.28 | 1.36 ± 0.30 | 1.33 ± 0.31 | 1.31 ± 0.32 |
| Anemia treatments (past 3–4 months) | |||||
| IV iron (with any dose), % | 33 | 21 | 32 | 39 | 48 |
| IV iron (mg/week) among treated, mean ± SD | 32 ± 21 | 29 ± 17 | 32 ± 25 | 31 ± 19 | 35 ± 20 |
| Bolusa dose of IV iron among treated, % | 17 | 22 | 18 | 15 | 15 |
| ESA (with any dose), % | 90 | 83 | 90 | 94 | 95 |
| ESA (1000 units/week) among treated, mean ± SD | 6 ± 5 | 6 ± 5 | 5 ± 4 | 5 ± 4 | 6 ± 5 |
| Transfused, % | 2 | 2 | 2 | 2 | 3 |
| Anemia labs, mean ± SD | |||||
| Ferritin (ng/mL) | 145 ± 205 | 26 ± 12 | 72 ± 15 | 141 ± 29 | 415 ± 311 |
| TSAT (%) | 26.1 ± 12.0 | 21.1 ± 11.0 | 26.3 ± 10.6 | 28.6 ± 10.7 | 31.4 ± 13.6 |
| Hemoglobin (g/dL) | 10.7 ± 1.2 | 10.8 ± 1.2 | 10.8 ± 1.1 | 10.7 ± 1.1 | 10.4 ± 1.3 |
| Nutrition and inflammation markers, mean ± SD | |||||
| Body mass index (kg/m2) | 21.5 ± 3.5 | 21.8 ± 3.5 | 21.5 ± 3.7 | 21.4 ± 3.4 | 21.0 ± 3.1 |
| Normalized PCR (g/kg/day) | 0.92 ± 0.21 | 0.93 ± 0.19 | 0.92 ± 0.21 | 0.92 ± 0.22 | 0.92 ± 0.22 |
| Serum phosphorus (mg/dL) | 5.3 ± 1.3 | 5.5 ± 1.3 | 5.3 ± 1.3 | 5.1 ± 1.3 | 5.2 ± 1.3 |
| Serum bicarbonate (mEq/L) | – | – | – | – | – |
| Serum potassium (mEq/L) | 4.8 ± 0.8 | 4.9 ± 0.7 | 4.8 ± 0.8 | 4.8 ± 0.8 | 4.8 ± 0.8 |
| Serum creatinine (mg/dL) | 10.4 ± 2.9 | 10.9 ± 3.0 | 10.4 ± 2.8 | 10.1 ± 2.8 | 9.9 ± 3.0 |
| Serum albumin (g/dL) | 3.70 ± 0.41 | 3.71 ± 0.40 | 3.70 ± 0.40 | 3.72 ± 0.39 | 3.67 ± 0.45 |
| WBC count (1000 cells/mm3) | 5.9 ± 1.9 | 6.0 ± 1.9 | 5.8 ± 1.9 | 5.8 ± 1.9 | 5.9 ± 2.0 |
| CRP (mg/L), median (IQR) | 1 (1–3) | 1 (1–3) | 1 (0–3) | 1 (0–3) | 1 (1–5) |
| Hospitalized in past 3–4 months, % | 10 | 10 | 9 | 9 | 11 |
| Comorbid conditions, % | |||||
| Coronary artery disease | 27 | 26 | 28 | 27 | 29 |
| Congestive heart failure | 19 | 19 | 17 | 20 | 19 |
| Cerebrovascular disease | 12 | 12 | 12 | 12 | 14 |
| Peripheral vascular disease | 16 | 16 | 17 | 18 | 14 |
| Other cardiovascular disease | 25 | 24 | 26 | 24 | 26 |
| Hypertension | 80 | 78 | 80 | 80 | 85 |
| Diabetes | 40 | 41 | 38 | 40 | 38 |
| Neurologic disease | 7 | 5 | 7 | 8 | 7 |
| Psychiatric disorder | 5 | 5 | 5 | 5 | 6 |
| Lung disease | 4 | 3 | 4 | 3 | 5 |
| Cancer (nonskin) | 11 | 10 | 9 | 11 | 14 |
| Gastrointestinal bleeding | 5 | 6 | 4 | 3 | 5 |
| Recurrent cellulitis, gangrene | 4 | 4 | 4 | 3 | 4 |
Serum bicarbonate was not measured in 80% of Japanese patients.
a
Defined as at least 1 month (of prior 3–4 months) with IV iron dose ≥500 mg.